VANCOUVER, BC / ACCESSWIRE / January 26, 2017 / (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) has retained the services of Cozen O’Connor. The Philadelphia-based law firm will work with CVR to obtain and protect patents related to the technology being implemented in the “Carotid Stenotic Scan (CSS)” device.
One of the largest and most successful law firms in the United States, Cozen O’Connor has built a global brand with a diverse list of clients across varying industries. Their expertise with patent law specific to the fields of science and medicine will lend support and defense to CVR’s intellectual property as it goes through the process of FDA approvals. In addition, the firm’s experience managing patent portfolios for companies in early-growth stages will strengthen CVR’s position as it moves beyond market launch of the CSS. CVR Medical CEO Peter Bakema, on this partnership, states, “It has always been of great importance to us to have the best practices, and the best people, in place to protect this incredible technology we’ve developed. We could not be happier to have found those people at Cozen O’Connor, and we look forward to having their guidance to help maximize the opportunities that technology presents.”
On behalf of Cozen O’Connor, Mr. Kyle Vos Strache states, “There’s real risk to being a pioneer, to challenging the status quo. What we see in the CVR team is a dedication to developing and implementing a technology that can really change the healthcare industry. We’re excited to be a part of that, and for us that means being proactive and ready to protect the product, as well as the company, as they evolve.”
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
ON BEHALF OF THE BOARD:
(signed) “Peter Bakema” CEO, President & Director
For further information contact:
Brisco Capital Partners Corp. Scott Koyich, President Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward- looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.